Shanghai InnoStar Bio-tech Co EBIT per osake

Mitä Shanghai InnoStar Bio-tech Co tekee? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co on yksi Eurpooliin suosituimmista yhtiöistä.